Monalizumab (Anti-Human CD159a)

Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors.
Supplier Selleck Chemicals
Product # A2053
Sku # A2053-1mg*25
Pricing 1mg*25, $5990.00
Feedback